Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 28, Issue 1, Pages 51-71Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2019.1551357
Keywords
Heart failure; novel investigational drugs; clinical trials; acute heart failure; reduced ejection fraction; preserved ejection fraction
Categories
Funding
- Ministerio de Ciencia e Innovacion [SAF2017-88116-P]
- Instituto de Salud Carlos III [PI16/00398, CB16/11/00303]
- Comunidad de Madrid [B2017/BMD-3738]
- Sociedad Espanola de Cardiologia
- BBVA Foundation
Ask authors/readers for more resources
Introduction: Heart failure (HF) represents a major health problem because of its high prevalence, high rates of hospitalizations, and mortality and significant healthcare costs. HF comprises a heterogeneous group of syndromes with different pathophysiology, clinical presentations, and response to therapy. Basic research has identified multiple putative therapeutic targets involved in the pathogenesis of HF and many promising drugs are under development. Areas covered: This review summarizes the main drugs currently in preclinical and clinical development for HF treatment. Drugs were identified by search of MEDLINE and PubMed and trials from registries (clinicaltrials.gov, clinicaltrialsregister.eu, pubmed.gov) from 2010. Expert opinion: Despite significant advances in the pharmacological treatment of HF with reduced ejection fraction, no treatment has yet convincingly shown to improve outcomes in patients with HF with preserved ejection fraction and acute HF. Many promising drugs emerged in preclinical models and small phase 2 trials, but with a few exceptions, they fail to meet the primary endpoints in larger adequately powered phase 3 trials. Which new drugs will prove valuable remains uncertain. Improving clinical outcomes, delaying or preventing HF worsening and reducing hospital admissions should be prioritized in future drug development programs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available